Acción 1877 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Shanghai Junshi Biosciences Co., Ltd.

Acciones

1877

CNE100003FF7

Mercado cerrado - Hong Kong S.E.
Otros sitios de cotización
 10:08:42 28/06/2024 		Varia. Cinco días. Varia. 1 de enero.
11,7 HKD -0,51 % Gráfico intradía de Shanghai Junshi Biosciences Co., Ltd. +3,72 % -39,81 %
26/06 El fármaco contra el cáncer de mama de Shanghai Junshi Biosciences obtiene el RDC de la NMPA; las acciones suben un 8 MT
25/06 Shanghai Junshi Biosciences Co., Ltd. Recibe el Certificado de Registro de Medicamentos emitido por la Administración Nacional de Productos Médicos CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Shanghai Junshi Biosciences Breast Cancer Drug Obtains DRC from NMPA; Shares Jump 8%
Shanghai Junshi Biosciences Co., Ltd. Receives the Drug Registration Certificate Issued by the National Medical Products Administration
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Advanced TNBC
Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer
Shanghai Junshi Biosciences Co., Ltd Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer
Junshi Biosciences' Cancer Drug Gets Registration Certificate from Chinese Regulator
Shanghai Junshi Biosciences Co., Ltd. Receives Drug Registration Certificate Issued by the National Medical Products Administration
Junshi Bio Achieves Primary Endpoints in Phase 3 Trial of Liver Cancer Treatment
Shanghai Junshi Biosciences Cancer Drug Shows Positive Phase III Trial Results
Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint
Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma
Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Shanghai Junshi Biosciences Receives Hong Kong Approval for Cancer Drug Toripalimab
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region
Shanghai Junshi Biosciences Co., Ltd. Announces Executive Changes
Junshi Biosciences Gets Nod to Register Toripalimab Injection
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción 1877
  4. Noticias Shanghai Junshi Biosciences Co., Ltd.
  5. Otros idiomas